TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the upcoming schedule of presentations highlighting BRIUMVI® (ublituximab-xiiy) data in patients with relapsing forms of multiple sclerosis (RMS), ...

JADE101 Phase 1 healthy volunteer interim data expected in the second quarter of 2026; Phase 2 clinical trial in patients with IgA nephropathy ...

Invivyd, Inc. (NASDAQ:IVVD) Q4 2025 Earnings Call Transcript March 5, 2026 Invivyd, Inc. misses on earnings expectations. Reported EPS is $-0.06428 EPS, expectations were $-0.06. Operator: Good day, ...

New research advances an Epstein–Barr virus vaccine, while another study detects higher levels of microplastics in prostate cancer tumors.

A Study shows mutation-resistant antibodies with 269×affinity, a proof point for CEPI’s 100 Days Mission and closing ...

Mirum Pharmaceuticals MIRM announced that it has completed enrollment in the phase III AZURE-1 study, evaluating its pipeline candidate, brelovitug, for the treatment of chronic hepatitis delta virus ...

Overall, the CUPID-C trial corroborates earlier evidence that dupilumab can meaningfully reduce itch and hives in ...

The new draft guidelines favor earlier DMARD therapy with ‘much decreased reliance on glucocorticoids that have several side ...

Everclear frontman Art Alexakis opens up about living with living with multiple sclerosis for more than a decade, the early signs he missed, and why he considers his diagnosis a "blessing.' ...

Although HIV infection remains a global public health challenge, ART has transformed it from a fatal illness to a manageable lifetime condition for those who are successfully being treated.Initially, ...

Jensen Investment Management, an asset management company based in the US, released its fourth-quarter investor letter for “Jensen Quality Growth Equity Strategy”.

A recent review identifies interleukin-36 (IL-36) as a transformative driver of vascular inflammation, revealing that serum concentrations in patients with coronary artery disease (CAD) are ...